Kintor PharmaceuticalKNTPF 24 PS Ratio is 24.63 as of Jul. 03, 2026, which is 75% below its 10-year median of 98.48. GuruFocus rates KNTPF with a GF Score™ of 24/100. The stock has 3 warning signs investors should review. Among 933 Biotechnology companies, Kintor Pharmaceutical ranks worse than 69.99% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Kintor Pharmaceutical's share price is $0.2463.
Kintor Pharmaceutical's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was $0.01. Hence, Kintor Pharmaceutical's PS Ratio for today is 24.63.
Good Sign:
Kintor Pharmaceutical Ltd stock PS Ratio (=24.88) is close to 1-year low of 23.13.
The historical rank and industry rank for Kintor Pharmaceutical's PS Ratio or its related term are showing as below:
KNTPF'
s PS Ratio Range Over the Past 10 Years
Min: 7.29 Med: 98.48 Max: 39375
Current: 25.51
During the past 8 years, Kintor Pharmaceutical's highest PS Ratio was 39375.00. The lowest was 7.29. And the median was 98.48.
KNTPF's PS Ratio is ranked worse than 69.99% of 933
companies
in the Biotechnology industry
Industry Median: 9.46
vs KNTPF: 25.51
During the past 8 years, Kintor Pharmaceutical's highest 3-Year average Revenue per Share Growth Rate was 289.30% per year. The lowest was -53.30% per year. And the median was 118.00% per year.
Back to Basics: PS Ratio
Kintor Pharmaceutical (OTCPK:KNTPF) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Kintor Pharmaceutical's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Kintor Pharmaceutical PS Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Kintor Pharmaceutical's PS Ratio distribution charts can be found below:
* The bar in red indicates where Kintor Pharmaceutical's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Kintor Pharmaceutical's Share Price of today is $0.2463.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Kintor Pharmaceutical's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was $0.01.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Kintor Pharmaceutical (KNTPF) has a PS Ratio of 24.63 as of Jul. 03, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Kintor Pharmaceutical and its competitors. This is 75% below median its historical median of 98.48. Over the past decade, Kintor Pharmaceutical's PS Ratio has ranged from 7.29 to 39,375.00. According to the industry distribution chart, Kintor Pharmaceutical ranks #653 out of 933 companies in the Biotechnology industry, placing it in the top 70%.
Is Kintor Pharmaceutical's PS Ratio too high?
Kintor Pharmaceutical's current PS Ratio of 24.63 is 75% below median its 10-year median of 98.48. Over the past 10 years, this metric has ranged from a low of 7.29 to a high of 39,375.00. The Biotechnology industry median PS Ratio is 9.46. Kintor Pharmaceutical's value of 24.63 is 160.4% above this industry median. Based on the distribution chart, Kintor Pharmaceutical ranks #653 out of 933 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Kintor Pharmaceutical has a GF Score™ of 24/100, reflecting its overall financial health beyond just this single metric.
How does Kintor Pharmaceutical's PS Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Kintor Pharmaceutical ranks #653 out of 933 companies for PS Ratio. This places Kintor Pharmaceutical in the lower half of its industry. The industry median PS Ratio is 9.46. Kintor Pharmaceutical's value of 24.63 is 160.4% above this benchmark. Historically, Kintor Pharmaceutical's own PS Ratio has ranged from 7.29 to 39,375.00 over the past decade. While the company's 10-year median is 98.48 vs. the industry median of 9.46, Kintor Pharmaceutical has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Biotechnology company?
The median PS Ratio among Biotechnology companies is 9.46, based on 933 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Kintor Pharmaceutical's current PS Ratio of 24.63 is 160.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Kintor Pharmaceutical and its competitors. For the Biotechnology industry, the median PS Ratio is 9.46 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Kintor Pharmaceutical's current PS Ratio is 24.63, which is 75% below median its own 10-year median of 98.48. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kintor Pharmaceutical stock overvalued right now?
Kintor Pharmaceutical (KNTPF) has a current PS Ratio of 24.63. The current PS Ratio is 24.63, which is 75% below median its 10-year median of 98.48 and 160.4% above the Biotechnology industry median of 9.46. Kintor Pharmaceutical's overall GF Score™ is 24/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Kintor Pharmaceutical (KNTPF), the current PS Ratio is 24.63 as of Jul. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Kintor Pharmaceutical Ltd is a clinical-stage novel drug developer in China, focusing on developing therapeutic drugs for unmet medical needs. Its pipelines cover indications of dermatology, such as AGA and acne vulgaris, and indications of tumors, catering to the unmet medical needs of patients and cosmetics consumers globally. The Group's cosmetic product types include anti-hair loss, acne treatment, and skin whitening products. Kintor's pipeline consists of various drug candidates such as KX-826, AR-PROTAC Compound (GT20029), GT1708F (Hedgehog/SMO Inhibitor), GT0486, and ALK-1 Antibody (GT90001). It has only one reportable operating segment, which is engaged in the research and development of medicine products and extends to functional cosmetics and raw materials.
24GF Score
Get the complete analysis for KNTPF
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
KNTPF has been successfully added to your 
